Latest Breaking News On - ப்ரையாரிடீ விமர்சனம் வவுச்சர் - Page 13 : comparemela.com

Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate

Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomJuan carlos jaramilloTeresa pinzolitsInstituto butantanCorporate communications specialistCorporate communicationsEuropean medicines agencyDrug administrationCoalition for epidemic preparedness innovationsCarlos jaramilloChief medical officerBiologics license applicationPriority review voucherLancet infectiousFast trackMiddle income countries

Incyte Corporation (NASDAQ:INCY) - FDA Accepts Incyte s Ruxolitinib Cream US Application For Chronic Skin Disease

Incyte Corporation (NASDAQ:INCY) - FDA Accepts Incyte s Ruxolitinib Cream US Application For Chronic Skin Disease
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Incyte corporationUnder priority reviewPriority review voucherகீழ் ப்ரையாரிடீ விமர்சனம்ப்ரையாரிடீ விமர்சனம் வவுச்சர்

(YMAB), United Therapeutics Corporation (NASDAQ:UTHR) - Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med

(YMAB), United Therapeutics Corporation (NASDAQ:UTHR) - Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Morgan stanleyUnited therapeutics corporationY mabs therapeutics incMemorial sloan kettering cancer centerBofa securitiesPriority review voucherMemorial sloan kettering cancerமோர்கன் ஸ்டான்லிஒன்றுபட்டது சிகிச்சை நிறுவனம்நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம்போஃபா பத்திரங்கள்ப்ரையாரிடீ விமர்சனம் வவுச்சர்நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய்

Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure

German NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021 Organization streamlined with a focus on cost savings and progressing vamorolone Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point Further strengthening of Santhera’s capital structure through a proposed convertible bond restructuring supported by its largest convertible bondholder representing approx. 32% of total bonds outstanding

Switzerland generalUnited statesEva kaliasDario eklundLife science allianceSanthera pharmaceuticalsSwiss financial services act finHead external communicationsDrug administrationSanthera pharmaceuticals holdingStifel nicolaus europeEuropean medicines agencyChiesi groupHighbridge tactical credit master fundHighbridge capital managementExtraordinary general meeting

Santhera Pharmaceuticals Holding AG: Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure

Santhera Pharmaceuticals Holding AG: Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021 Organization streamlined with a focus on cost savings and progressing vamorolone Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point

Switzerland generalUnited statesEva kaliasDario eklundSanthera pharmaceuticalsSwiss financial services act finHead external communicationsDrug administrationSanthera pharmaceuticals holdingStifel nicolaus europeEuropean medicines agencyHighbridge tactical credit master fundHighbridge capital managementExtraordinary general meetingSenior unsecured convertible bondsStifel nicolaus europe limited